Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiple Ascending Dose and Drug-Drug Interaction Study of DSP-0378 in Healthy Adults
jRCT2071260005Phase 1Recruiting
- Sponsor
- Sumitomo Pharma
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DSP-0378 in Benign adult familial myoclonic epilepsy (BAFME) (3 arms), sponsored by Sumitomo Pharma. Primary endpoints: Safety and tolerability (Part A), Pharmacokinetics of DSP-0378 (Part B) and 1 more. Started Apr 2026; status: recruiting.
02
Drugs
DSP-0378
03
Conditions
Benign adult familial myoclonic epilepsy (BAFME)
Beyond the preview
Go deeper on jRCT2071260005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071260005.